Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT ID: NCT02506023

Last Updated: 2018-07-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2018-06-15

Brief Summary

The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).

Detailed Description

DDAVP (Desmopressin) is commonly used in the treatment of persons with bleeding disorders such as hemophilia, von Willebrand disease, or qualitative platelet disorders to help them clot better. The investigator wants to assess the increase in the subjects' clotting factors in response to intravenous DDAVP (Desmopressin) and the levels of these internal clotting factors will be measured at different times after the medication is given. The investigator will compare the response to DDAVP (Desmopressin) in adult hemophilia A carriers to women with a diagnosis of qualitative platelet dysfunction.

Conditions

Hemophilia A

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Hemophilia A carriers with mild mutation

Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).

Group Type: ACTIVE_COMPARATOR

Desmopressin

Intervention Type: DRUG

Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Hemophilia A Carriers with severe mutation

Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).

Group Type: ACTIVE_COMPARATOR

Desmopressin

Intervention Type: DRUG

Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Control

Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).

Group Type: ACTIVE_COMPARATOR

Desmopressin

Intervention Type: DRUG

Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Interventions

Desmopressin

Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Intervention Type: DRUG

Other Intervention Names

DDAVP

Eligibility Criteria

Inclusion Criteria

• Females 18-60 years of age at time of enrollment
• Genetically verified or obligate hemophilia A carrier (mother of 2 boys with hemophilia A, daughter of a father with hemophilia A or mother of a son and another male relative with hemophilia A)
• To stratify patients by carriage of mutation type 10 hemophilia carriers of mild mutations that are predicted to lead to reduced FVIII secretion, protein stability or thrombin cleavage site interference and 10 hemophilia carriers of severe mutations that lead to predicted negative cross reactive material will be selected. Predicted FVIII function of the mutation will be verified by EAHAD (European Association for Haemophilia and Allied Disorders) Coagulant Factor Variant Database at www.eahad-db.org)
• Weight >40kg to ensure volumes of blood to be drawn are within accepted safe range

• Females 18-60 years of age at time of enrollment
• Whole blood or platelet rich plasma lumiaggregometry consistent with reduced aggregation to at least 1 agonist on at least one occasion (excluding evidence of Glanzmanns Thrombasthenia or Bernard Soulier Syndrome) or determined by primary hematologist as having a qualitative platelet disorder
• Age-matched by 10 years to carrier enrolled
• Weight >40kg to ensure volumes of blood to be drawn are within accepted safe range

Exclusion Criteria

• Personal history of concomitant bleeding or clotting disorder
• Cardiac condition that requires the daily use of Aspirin or Clopidogrel
• Inability to comply with fluid restriction protocol for 24 hours following Desmopressin (DDAVP)
• Personal history of a myocardial infarction, renal or hepatic insufficiency or epilepsy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Emory University

OTHER

Sponsor Role: lead

Responsible Party

Robert Sidonio

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert Sidonio, Jr., MD

Role: PRINCIPAL_INVESTIGATOR

Emory University

Locations

Children's Hospital of Atlanta Egleston

Atlanta, Georgia, United States

Emory University

Atlanta, Georgia, United States

Countries

United States

Other Identifiers

IRB00080329

Identifier Type: -

Identifier Source: org_study_id